Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $464,046 | 232 | 82.8% |
| Consulting Fee | $42,598 | 20 | 7.6% |
| Food and Beverage | $30,878 | 629 | 5.5% |
| Travel and Lodging | $22,562 | 111 | 4.0% |
| Education | $61.10 | 3 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Biogen, Inc. | $115,571 | 123 | $0 (2024) |
| EMD Serono, Inc. | $76,734 | 132 | $0 (2024) |
| ABBVIE INC. | $56,505 | 154 | $0 (2024) |
| Acorda Therapeutics, Inc | $55,190 | 58 | $0 (2022) |
| GENZYME CORPORATION | $46,032 | 79 | $0 (2024) |
| Genentech USA, Inc. | $44,934 | 58 | $0 (2021) |
| Biohaven Pharmaceuticals, Inc. | $44,713 | 45 | $0 (2021) |
| Biohaven Pharmaceutical Holding Company Ltd. | $38,481 | 39 | $0 (2022) |
| E.R. Squibb & Sons, L.L.C. | $37,505 | 45 | $0 (2024) |
| Allergan, Inc. | $9,981 | 25 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $46,587 | 106 | ABBVIE INC. ($26,298) |
| 2023 | $78,251 | 146 | ABBVIE INC. ($29,644) |
| 2022 | $111,193 | 198 | Biohaven Pharmaceutical Holding Company Ltd. ($38,481) |
| 2021 | $89,174 | 148 | Biohaven Pharmaceuticals, Inc. ($43,588) |
| 2020 | $68,568 | 85 | Acorda Therapeutics, Inc ($27,615) |
| 2019 | $96,219 | 150 | Genentech USA, Inc. ($25,887) |
| 2018 | $61,178 | 113 | Biogen, Inc. ($37,643) |
| 2017 | $8,975 | 49 | EMD Serono, Inc. ($7,618) |
All Payment Transactions
995 individual payment records from CMS Open Payments — Page 1 of 40
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | E.R. Squibb & Sons, L.L.C. | ZEPOSIA (Drug) | Travel and Lodging | Cash or cash equivalent | $212.20 | General |
| Category: Neuroscience | ||||||
| 12/27/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $18.42 | General |
| Category: NEUROSCIENCE | ||||||
| 12/20/2024 | Celgene Corporation | ZEPOSIA (Drug) | Consulting Fee | Cash or cash equivalent | $2,400.00 | General |
| Category: Neuroscience | ||||||
| 12/20/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $12.30 | General |
| Category: NEUROSCIENCE | ||||||
| 12/09/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $45.19 | General |
| 12/06/2024 | Celgene Corporation | ZEPOSIA (Drug) | Travel and Lodging | Cash or cash equivalent | $536.32 | General |
| Category: Neuroscience | ||||||
| 12/06/2024 | Celgene Corporation | ZEPOSIA (Drug) | Travel and Lodging | Cash or cash equivalent | $212.19 | General |
| Category: Neuroscience | ||||||
| 12/06/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $124.99 | General |
| Category: Neuroscience | ||||||
| 12/06/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $50.12 | General |
| Category: Neuroscience | ||||||
| 12/06/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $50.12 | General |
| Category: Neuroscience | ||||||
| 12/06/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $31.39 | General |
| Category: Neuroscience | ||||||
| 12/06/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $26.54 | General |
| Category: Neuroscience | ||||||
| 12/06/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $26.54 | General |
| Category: Neuroscience | ||||||
| 12/04/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| Category: Immunology | ||||||
| 11/21/2024 | GENZYME CORPORATION | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,906.00 | General |
| 11/21/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $121.36 | General |
| 11/15/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $8.75 | General |
| Category: Neuroscience | ||||||
| 10/30/2024 | UCB, Inc. | — | Food and Beverage | In-kind items and services | $128.51 | General |
| 10/11/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $7.93 | General |
| Category: Neuroscience | ||||||
| 10/08/2024 | ABBVIE INC. | QULIPTA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,625.00 | General |
| Category: NEUROSCIENCE | ||||||
| 10/02/2024 | UCB, Inc. | Zilbrysq (Biological) | Consulting Fee | Cash or cash equivalent | $1,140.00 | General |
| Category: Neurology | ||||||
| 09/26/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $8.12 | General |
| Category: NEUROSCIENCE | ||||||
| 09/19/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $104.99 | General |
| Category: NEUROLOGY | ||||||
| 09/19/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $20.00 | General |
| Category: NEUROLOGY | ||||||
| 09/18/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $8.96 | General |
| Category: NEUROSCIENCE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 368 | 479 | $112,842 | $57,627 |
| 2022 | 4 | 327 | 434 | $100,418 | $51,856 |
| 2021 | 5 | 330 | 427 | $95,235 | $50,277 |
| 2020 | 5 | 263 | 279 | $52,806 | $26,203 |
All Medicare Procedures & Services
19 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 202 | 308 | $68,530 | $37,932 | 55.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 96 | 96 | $30,403 | $14,167 | 46.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 26 | 28 | $4,638 | $2,286 | 49.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 19 | 19 | $4,762 | $2,065 | 43.4% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Facility | 2023 | 25 | 28 | $4,508 | $1,177 | 26.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 185 | 287 | $63,858 | $36,481 | 57.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 82 | 82 | $25,969 | $11,960 | 46.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 25 | 27 | $4,473 | $1,818 | 40.7% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Facility | 2022 | 35 | 38 | $6,118 | $1,597 | 26.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 114 | 190 | $42,895 | $25,331 | 59.1% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 78 | 78 | $24,952 | $12,391 | 49.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 82 | 102 | $16,635 | $8,475 | 50.9% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 26 | 26 | $6,412 | $2,676 | 41.7% |
| 95816 | Measurement and recording of brain wave (eeg) activity, awake and drowsy | Facility | 2021 | 30 | 31 | $4,342 | $1,404 | 32.3% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 71 | 84 | $16,539 | $7,980 | 48.3% |
| 99358 | Prolonged patient service without direct patient contact first hour | Office | 2020 | 69 | 69 | $11,648 | $5,969 | 51.2% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 34 | 34 | $9,238 | $5,242 | 56.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 67 | 70 | $10,871 | $4,414 | 40.6% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 22 | 22 | $4,510 | $2,597 | 57.6% |
About Dr. Michael Mazowiecki, MD
Dr. Michael Mazowiecki, MD is a Neurology healthcare provider based in Greensburg, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/19/2006. The National Provider Identifier (NPI) number assigned to this provider is 1841304581.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Mazowiecki, MD has received a total of $560,146 in payments from pharmaceutical and medical device companies, with $46,587 received in 2024. These payments were reported across 995 transactions from 32 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($464,046).
As a Medicare-enrolled provider, Mazowiecki has provided services to 1,288 Medicare beneficiaries, totaling 1,619 services with total Medicare billing of $185,963. Data is available for 4 years (2020–2023), covering 19 distinct procedure/service records.
Practice Information
- Specialty Neurology
- Location Greensburg, PA
- Active Since 08/19/2006
- Last Updated 01/26/2017
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1841304581
Products in Payments
- NURTEC ODT (Drug) $83,359
- QULIPTA (Drug) $55,702
- INBRIJA (Drug) $54,883
- OCREVUS (Biological) $44,829
- TYSABRI (Biological) $43,702
- ZEPOSIA (Drug) $37,545
- VUMERITY (Drug) $33,145
- Mavenclad (Drug) $30,398
- TECFIDERA (Drug) $27,288
- LEMTRADA (Drug) $20,856
- MAVENCLAD (Drug) $15,877
- Mavenclad (Biological) $11,637
- UBRELVY (Drug) $10,624
- EMGALITY (Drug) $8,118
- Rebif (Biological) $7,624
- WAKIX (Drug) $5,417
- Ponvory (Drug) $5,185
- DISEASE STATE (Drug) $2,352
- AUBAGIO (Drug) $1,898
- VNS Therapy (Device) $1,346
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Greensburg
Louis Catalano, Md, MD
Neurology — Payments: $70,274
Austin Oblack, Do, DO
Neurology — Payments: $35,447
Dr. Mary Kovacik Eicher, M.d, M.D
Neurology — Payments: $22,498
Vijayalakshmi Ragoor, Md, MD
Neurology — Payments: $10,096
Seth Cahn, Md, MD
Neurology — Payments: $1,653
Martha Haykin, Md, MD
Neurology — Payments: $165.33